“Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 ” (2022) SKIN The Journal of Cutaneous Medicine, 6(2), p. s2. doi:10.25251/skin.6.supp.2.